awmsg logo



ulipristal acetate (Esmya®)


Reference No. 2767

Publication date:
12/04/2016


Last review date:
20/01/2017

Appraisal information

ulipristal acetate (Esmya®) 5 mg tablet


Company: Gedeon Richter UK Ltd
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 10/02/2016
AWMSG meeting date: 23/03/2016
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0716
Ministerial ratification: 05/04/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ulipristal acetate (Esmya®) is recommended as an option for use within NHS Wales for the intermittent treatment or pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download